Galapagos NV ADR - Asset Resilience Ratio
Galapagos NV ADR (GLPG) has an Asset Resilience Ratio of 86.45% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check GLPG capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Galapagos NV ADR's Asset Resilience Ratio has changed over time. See how leveraged is Galapagos NV ADR's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Galapagos NV ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Galapagos NV ADR (GLPG) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.92 Billion | 86.45% |
| Total Liquid Assets | $2.92 Billion | 86.45% |
Asset Resilience Insights
- Very High Liquidity: Galapagos NV ADR maintains exceptional liquid asset reserves at 86.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Galapagos NV ADR Industry Peers by Asset Resilience Ratio
Compare Galapagos NV ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Galapagos NV ADR (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Galapagos NV ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 85.43% | $2.91 Billion | $3.41 Billion | +11.60pp |
| 2024-12-31 | 73.83% | $3.05 Billion | $4.14 Billion | -6.90pp |
| 2023-12-31 | 80.73% | $3.52 Billion | $4.36 Billion | +4.99pp |
| 2022-12-31 | 75.74% | $3.59 Billion | $4.73 Billion | +28.18pp |
| 2021-12-31 | 47.56% | $2.47 Billion | $5.19 Billion | -5.37pp |
| 2020-12-31 | 52.93% | $3.03 Billion | $5.72 Billion | -11.65pp |
| 2019-12-31 | 64.58% | $3.92 Billion | $6.07 Billion | -- |
| 2018-12-31 | 0.00% | $0.00 | $1.44 Billion | -- |
| 2017-12-31 | 0.00% | $0.00 | $1.29 Billion | -- |
| 2014-12-31 | 4.66% | $12.61 Million | $270.47 Million | -- |
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more